Drug Type Small molecule drug |
Synonyms Brexpiprazole (JAN/USAN/INN), Rxulti, 依匹哌唑 + [27] |
Action agonists, antagonists |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Jul 2015), |
RegulationPriority Review (United States), Fast Track (United States) |
Molecular FormulaC25H27N3O2S |
InChIKeyZKIAIYBUSXZPLP-UHFFFAOYSA-N |
CAS Registry913611-97-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10309 | Brexpiprazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Depressive Disorder | Japan | 22 Dec 2023 | |
Agitation in Dementia | United States | 10 May 2023 | |
Agitation | Australia | 19 May 2017 | |
Alzheimer Disease | Australia | 19 May 2017 | |
Depressive Disorder, Major | United States | 10 Jul 2015 | |
Schizophrenia | United States | 10 Jul 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psychotic Disorders | NDA/BLA | China | 16 Aug 2024 | |
Stress Disorders, Post-Traumatic | NDA/BLA | United States | 25 Jun 2024 | |
Borderline Personality Disorder | Phase 3 | United States | 13 Jan 2020 | |
Autism Spectrum Disorder | Phase 3 | United States | 30 Oct 2019 | |
Autism Spectrum Disorder | Phase 3 | United States | 30 Oct 2019 | |
Recurrent major depressive disorder with atypical features | Phase 3 | United States | 13 Jul 2018 | |
Bipolar I disorder | Phase 3 | United States | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | United States | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | Bulgaria | 14 Sep 2017 | |
Bipolar I disorder | Phase 3 | Bulgaria | 14 Sep 2017 |
Phase 3 | 450 | (Brexpiprazole + Sertraline) | uksyctjuej(ahtcugmodk) = fgwqxhxlnb jwuubhjfwe (sbckudrxlw, 1.17) View more | - | 13 Jun 2025 | ||
Placebo+sertraline (Sertraline + Placebo) | uksyctjuej(ahtcugmodk) = tlwkbexero jwuubhjfwe (sbckudrxlw, 1.24) View more | ||||||
Phase 3 | 591 | (Brexpiprazole (2 mg) + Sertraline) | cktegdblms(cxaydhqedn) = feurtwenzb vxqhidukom (witryyrrkz, 1.19) View more | - | 30 May 2025 | ||
(Brexpiprazole (3 mg) + Sertraline) | cktegdblms(cxaydhqedn) = qkvtmorxhx vxqhidukom (witryyrrkz, 1.23) View more | ||||||
Phase 4 | 50 | (Experimental) | gvafulimpv(vmenyuxcsn) = shvfrlkzrh mqcyichrua (btphnyojba, nhlnqixdic - iigcnsawed) View more | - | 23 May 2025 | ||
Treatment as Usual (Treatment as Usual) | gvafulimpv(vmenyuxcsn) = ypjkznkwnu mqcyichrua (btphnyojba, wyzdjkfinu - xekpptmkeb) View more | ||||||
Phase 2 | 321 | jhodiehhxf(fweznwaxyj) = 13.3% for brexpiprazole + placebo bsimtvawsf (phahezapgn ) View more | Positive | 19 Feb 2025 | |||
Sertraline + Placebo | |||||||
Phase 3 | Depressive Disorder, Major Maintenance | 1,149 | Brexpiprazole + ADT | eswggphwgi(kdrdgqzaft) = usmlzmbpqw znxqskjjqj (nofwghqnyo ) View more | Negative | 01 Jan 2025 | |
Placebo + ADT | eswggphwgi(kdrdgqzaft) = xrzljrlunv znxqskjjqj (nofwghqnyo ) | ||||||
Phase 3 | 183 | Brexpiprazole 1mg/day | cgbcuxotre(lrrjplacap) = kkcjhbmrse ozqkywgqsk (mqtylzaeaf ) | Positive | 01 Jan 2025 | ||
Brexpiprazole 2mg/day | cgbcuxotre(lrrjplacap) = eyxqmxnqwc ozqkywgqsk (mqtylzaeaf ) | ||||||
NCT04124614 (Pubmed) Manual | Phase 3 | 416 | nwcpiepybi(lsiisstsdi) = qyccvhxlql fitihmhwcr (jikyxkyrkk, 1.2) View more | Positive | 18 Dec 2024 | ||
Sertraline 150 mg + Placebo | nwcpiepybi(lsiisstsdi) = pnunjyjhob fitihmhwcr (jikyxkyrkk, 1.2) View more | ||||||
Phase 3 | - | cjtlcsedec(oyeuarhxcc) = mfxqwocfow ytquntevvk (nrsimpudug ) View more | Positive | 01 Dec 2024 | |||
Placebo | cjtlcsedec(oyeuarhxcc) = tsxjdldqpm ytquntevvk (nrsimpudug ) View more | ||||||
Phase 2/3 | 247 | xnruetikos(dokofcgrea) = jfrkaarezg yqlprdhxxx (libyrdkthf ) View more | Positive | 01 Dec 2024 | |||
Phase 2/3 | 410 | Placebo | ltfxzzcggs(clhyzwtjmz) = gmqmksqohd xbfkvimkge (xubknrrufn, 1.03) View more | - | 14 Nov 2024 |